基于当前市场动态和研发进展，健康原料领域正朝着更精准、高效和个性化的方向发展，展现出广阔前 景。以下从几个关键趋势和具体原料进行分析： 核心趋势：精准化与场景化升级 由北京千和展览有限公司承办的2026第3届北京国际天然提取物及健康原料展览会（简称EPRM天然原 料展）将于2026年10月29-31日在北京亦创国际会展中心隆重举行、深度展示天然提取物与健康原料领 域的最新发展趋势，为企业搭建合作交流平台，推动行业高质量发展。 磷脂Omega-3（来自磷虾油）：具有高效作用于细胞的特性，对维护心脏健康等有显著作用。 依托南极纯净原料和专利技术，其供应链和功效得到进一步保障。 麦角硫因：虽在国内尚未正式获批为新食品原料，但已在美、欧、日等地广泛应用。其作为核心 成分在化妆品和膳食补充剂中备受青睐，科技突破已有效缓解了其稀缺性和成本问题。1 母乳低聚糖（HMOs）：作为母乳中的核心成分，其在婴幼儿配方奶粉及普通食品中的应用受到 高度关注。 全球法规环境日益完善，例如美国FDA已批准其用于多种食品，中国也已批准特定HMOs作为营 养强化剂，市场进入快速发展期。2 还原型辅酶Q10：通过精密发酵技术，其生物利用率得到大 ...

Core Insights - Kaneka's participation in the China International Import Expo (CIIE) is a strategic move to align with China's "Healthy China 2030" initiative and tap into the growing health market in China [2][10] - The company aims to position itself not just as a raw material supplier but as a "value partner" for Chinese brands, providing comprehensive support in product development and market education [3][8] Company Strategy - Kaneka has over 45 years of research and development experience in coenzyme Q10, with more than 100 scientific studies and over 80 global patents backing its products [1][2] - The company recognizes the rapid upgrade of China's health consumption market and sees it as a core driver for global business growth [2][6] Product Offering - Kaneka's reduced form of coenzyme Q10 is produced using advanced Japanese fermentation technology, achieving global leadership in purity, stability, and bioavailability [3][4] - This product has a bioavailability that is 3-8 times higher than that of regular coenzyme Q10, allowing for direct absorption without conversion in the body [3][9] Quality Control - Kaneka maintains a stringent quality control system, ensuring that every batch of raw materials exceeds industry standards through scientific testing and third-party verification [4][7] - The company emphasizes consistency in quality, regardless of production scale, which has earned it the trust of over a thousand global brands [4][7] Market Education - Kaneka aims to educate the Chinese market about mitochondrial health, which is currently not widely recognized, by collaborating with medical professionals and social media influencers [5][10] - The company draws parallels to the rise in awareness of gut health over the past decade, hoping to make mitochondrial health a core concept among Chinese consumers [5][6] Target Demographics - The primary consumer group for Kaneka's coenzyme Q10 in China includes middle-aged and elderly individuals focused on cardiovascular health and energy metabolism [6][10] - There is also a growing segment of female consumers interested in reproductive health and skin improvement, indicating a broad market potential [6][10] Competitive Positioning - Compared to mature markets, Chinese consumers prioritize scientific evidence and brand reputation when selecting health products, aligning with Kaneka's product philosophy [7][10] - Kaneka plans to tailor its product solutions to meet local consumer needs while continuing to promote the benefits of its coenzyme Q10 [7][10] Future Directions - Kaneka sees significant potential in the mitochondrial health sector and aims to innovate continuously, exploring new applications for its coenzyme Q10 [9][10] - The company is committed to collaborating with global research institutions to expand its product development directions and enhance its market offerings [9][10]

Core Viewpoint - The company, Jindawei, has advanced production technology and scale, holding multiple invention patents, including reduced coenzyme Q10, in China and the United States [1] Group 1: Company Overview - Jindawei has a leading position in production technology and scale [1] - The company possesses several invention patents related to reduced coenzyme Q10 [1] Group 2: Market Analysis - The sales proportion of reduced coenzyme Q10 in the market is currently low [1] - The company has conducted research and analysis on the market prospects for reduced coenzyme Q10 [1]